BMY’s Big Dividend and Bigger Gamble

Now, if you’ve been sittin’ on the fence ’bout dividend stocks, let me tell you ’bout Bristol Myers Squibb. They’ve been dancin’ with a dividend for 25 years, like a riverboat gambler who never misses a bet. Their stock’s yield? A whopping 5.5%-that’s enough to make the average S&P 500 investor blush like a schoolgirl caught with her fingers in the cookie jar.

But here’s the rub: This fine establishment’s lost exclusivity on Revlimid, their old reliable cash cow, and soon they’ll have to hand over Eliquis to the patent wolves. It’s like watchin’ your favorite mule get sold at auction-nobody wants to see it happen, but there it is.

Now, you might say, “Why in tarnation would I buy this stock?” Well, I’ll tell you. They’ve got a new crop of treatments growin’ like weeds in a Mississippi delta. Seven of ’em saw double-digit sales jumps last quarter-Breyanzi, their cell-based cancer cure, doubled sales like a frog with wings. And Cobenfy? That’s their new schizophrenia remedy, sittin’ pretty with $2.6 billion in the crosshairs by 2030. It’s the kind of future that makes a man forget his worries and start countin’ his dollars.

The books? They’re expectin’ $6.35 to $6.65 per share in earnings-more than enough to keep that dividend spigot flowin’ at $2.48 a year. And with new drugs in the pipeline, this high-yield wonder might keep its charm for another decade. But mind you, it’s a gamble. Like buyin’ a ticket to a steamboat race where the boat’s got a few leaks. But hey, so’s life. 🦆

2025-09-23 10:55

Read More